Zaida Garcia-Casado

Zaida Garcia-Casado

Auto-generated profile, based on publicly available information

Zaida Garcia-Casado

Laboratory of Molecular Biology, Fundación Instituto Valenciano de Oncología, Valencia, Spain

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2010 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ZGZaida Garcia-Casado
Zaida Garcia-Casado
AGAngel Guerrero-Zotano
Angel Guerrero-Zotano
ALAntonio Llombart-Cussac
Antonio Llombart-Cussac
ACAna Calatrava
Ana Calatrava
AFAntonio Fernandez-Serra
Antonio Fernandez-Serra
JOSE ANTONIO LOPEZ-GUERREROJOSE ANTONIO LOPEZ-GUERRERO
JOSE ANTONIO LOPEZ-GUERRERO
Background: Aromatase (CYP19A1) regulates estrogen biosynthesis. Polymorphisms inCYP19A1have been related to the pathogenesis of breast cancer (BC). Inhibition of aromatase with letrozole constitutes the best option for treating estrogen-dependent BC in postmenopausal women. We evaluate a series of polymorphisms ofCYP19A1and their effect on response to neoadjuvant letrozole in early BC.Methods: We analyzed 95 consecutive postmenopausal women with stage II-III ER/PgR [+] BC treated with neoadjuvant letrozole. Response to treatment was measured by radiology at 4thmonth by World Health Organization (WHO) criteria. Three polymorphisms ofCYP19A1, one in exon 7 (rs700519) and two in the 3'-UTR region (rs10046 and rs4646) were evaluated on DNA obtained from peripheral blood.Results: Thirty-five women (36.8%) achieved a radiological response to letrozole. The histopathological and immunohistochemical parameters, including hormonal receptor status, were not associated with the response to letrozole. Only the genetic variants (AC/AA) of the rs4646 polymorphism were associated with poor response to letrozole (p = 0.03). Eighteen patients (18.9%) reported a progression of the disease. Those patients carrying the genetic variants (AC/AA) of rs4646 presented a lower progression-free survival than the patients homozygous for the reference variant (p = 0.0686). This effect was especially significant in the group of elderly patients not operated after letrozole induction (p = 0.009).Conclusions: Our study reveals that the rs4646 polymorphism identifies a subgroup of stage II-III ER/PgR [+] BC patients with poor response to neoadjuvant letrozole and poor prognosis. Testing for the rs4646 polymorphism could be a useful tool in order to orientate the treatment in elderly BC patients.